May & Baker Nigeria PLC

The company maintains a relatively strong liquidity position, with NGN 4.13 billion in cash and equivalents, but its long-term debt of NGN 6.32 billion exceeds its cash reserves, resulting in a net cash deficit. The debt-to-equity ratio of 0.67 suggests a moderate level of leverage, while the current ratio of 1.53 indicates that the company can cover its short-term obligations with its current assets. The return on equity of 6.94% is below the typical benchmark for pharmaceutical firms, suggesting that the company is not generating strong returns for its shareholders.

Profitability metrics show a gross profit of NGN 2.33 billion and an operating income of NGN 1.02 billion, translating to a gross margin of 36.2% and an operating margin of 15.8%. These figures are in line with the industry median for pharmaceutical firms, but the net income of NGN 655.4 million, or a net margin of 10.2%, is slightly below the median for the sector. The return on assets of 2.86% is also below the industry average, indicating that the company is not efficiently utilizing its asset base to generate returns.

The company's revenue is concentrated in a single geographic market, Nigeria, which accounts for the entirety of its reported revenue. There is no disclosed segmental breakdown, but the lack of geographic diversification increases exposure to local economic and regulatory risks. The company does not report revenue by product line or therapeutic area, making it difficult to assess the drivers of its performance.

Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the next fiscal year. The capital expenditure of NGN 271.3 million is relatively modest, suggesting a conservative approach to reinvestment. The free cash flow of NGN 518.6 million provides some flexibility for dividends or debt reduction, but the company's leverage position remains a concern.

The risk assessment highlights a medium liquidity risk due to the net cash deficit and a low dilution risk, as the company has not issued additional shares in the recent period. The key flag of negative net cash after subtracting total debt suggests that the company may need to raise additional capital or reduce debt in the near term. The analyst price target of NGN 24.76 is uniform across all estimates, indicating a consensus view of the stock's fair value.

Recent filings and transcripts do not indicate any material changes in the company's operations or strategy. The company continues to operate in a highly regulated environment, and any changes in Nigerian healthcare policy could impact its business model.

Revenue grew 46.8% year-over-year to NGN 28.9 billion, demonstrating strong top-line expansion momentum.

Free cash flow surged 348% year-over-year to NGN 567.6 million, highlighting robust cash generation capabilities.

Cash conversion ratio of 2.17 ranks in the top quartile, surpassing the cohort median of 0.95.

The stock trades at NGN 42.3, implying a 41.5% downside to the single analyst consensus target price.

Debt-to-equity ratio of 0.67 places the company in the bottom quartile compared to the sector median of 0.18.

Medium liquidity risk flags suggest potential challenges in trading volume or market depth for investors.

Medium credit risk indicates potential concerns regarding the company's ability to meet its financial obligations.

Net income CAGR of 11.5% over four years lags behind the 24.8% revenue growth rate.

Revenue NGN 38.26B, +32,4% YoY; Operating income +146,7% YoY.

• ▍Revenue NGN 38.26B, +32,4% YoY
• ▍Operating income +146,7% YoY
• ▍Net income +173,7% YoY
• ▍Free cash flow +497,7% YoY
• ▍Net margin 11.6%

Revenue NGN 14.33B, +20,4% YoY; Operating income +27,2% YoY.

• ▍Revenue NGN 14.33B, +20,4% YoY
• ▍Operating income +27,2% YoY
• ▍Net income +42,0% YoY
• ▍Free cash flow −132,2% YoY
• ▍Net margin 10.4%

Revenue NGN 11.90B; Operating income NGN 1.70B.

• ▍Revenue NGN 11.90B
• ▍Operating income NGN 1.70B
• ▍Net margin 8.8%